<DOC>
	<DOCNO>NCT02589626</DOCNO>
	<brief_summary>This multi-center , randomise , double-blind , parallel-group , safety efficacy study empagliflozin add-on GLP-1 RA Japanese patient Type 2 Diabetes Mellitus insufficient glycaemic control</brief_summary>
	<brief_title>Long-term Safety Efficacy Empagliflozin Add GLP-1 RA</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>Inclusion criterion : Diagnosis type 2 diabetes mellitus Male female patient diet exercise regimen pretreated Liraglutide 0.9 mg/day alone least 10 week prior screen must &gt; =7.0 % &lt; =10.0 % screen Male female patient diet exercise regimen pretreated Liraglutide 0.9 mg/day one oral antidiabetic drug ( OAD ) least 10 week prior Visit 1 must &gt; =7.0 % &lt; =9.0 % screen &gt; =7.0 % &lt; =10.0 % placebo runin Male female patient diet exercise regimen pretreated OAD alone least 10 week prior Visit 1 must &gt; =7.0 % &lt; =10.0 % screen placebo runin Age inform consent must &gt; =20 year BMI screening must &lt; =40 kg/m2 Further inclusion criterion apply Exclusion criterion : Uncontrolled hyperglycaemia glucose value &gt; 270 mg/dL ( &gt; 15.0 mmol/L ) overnight fast switch/washout/placebo runin period confirm second measurement Patients drugna√Øve screen visit treat insulin , thiazolidine dione , SGLT2 inhibitor within 10 week prior inform consent . Acute coronary syndrome , stroke transient ischemic attack within 12 week prior inform consent Indication liver disease , define serum level either alanine aminotransferase , aspartate aminotransferase , alkaline phosphatase 3 x upper limit normal determine screen and/or switch/washout/placebo runin period Impaired renal function , define eGFR &lt; 45 mL/min/1.73m2 ( Japanese equation ) determine screen and/or switch/washout/placebo runin period Further exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>